reports
Corcept Therapeutics Inc: 1 director
A director at Corcept Therapeutics Inc sold 26,198 shares at 50.074USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Offic...
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced the appointment of Jeffrey A. Munsie as Chief Legal Officer. “Jeff brings deep life sciences experience across critical stages of growth, from preclinical through commercialization,” sai...
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing ...
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) RADNOR, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on March 16, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 27,920 shares and an inducement re...
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results a...
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update – Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldostero...
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrosta...
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results – The FDA assigned a PDUFA target action date of December 22, 2026 – – The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction in adults with hypertension – – Topline results from the Phase 2 Explore-OSA exploratory trial did not reduce AHI; demonstrated a clinically meaningful reduction in blood pressure and favorable safety and tolerability in this population with d...
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 F...
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026 RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2025, after the fina...
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing ...
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 23, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 27,920 shares and...
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing ...
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 9, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering 33,504 shares and in...
Mineralys Therapeutics Provides Corporate Update and Announces Partici...
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 RADNOR, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today issued a corporate update highlighting several recent and upcoming clinical and regulatory milestones. In...
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recog...
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup – Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful of 2025 by JAMA editors – RADNOR, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and...
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing R...
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on November 24, 2025, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 146,000 shares of ...
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results an...
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update – Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep ap...
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Prese...
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025 – Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company developing therapies to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dys...
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Mineralys Therapeutics to Participate in Upcoming Investor Conferences RADNOR, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that members of senior management will be participating in fireside chats at three upcoming investor conferences. Guggenheim Healthcare Innovation ConferenceDate:Tuesday...
Mineralys Therapeutics to Announce Third Quarter 2025 Financial Result...
Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025 RADNOR, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2025, after the financial markets ...
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2...
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025 ~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~~ Phase 3 data of the Launch-HTN Trial of lorundrostat to be included in “Best of Journal of the American Medical Association and the New England Journal of Medicine” presentation~ RADNOR, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: ML...
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Tri...
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension ~ Topline results from the EXPLORE-OSA trial are anticipated in 1Q 2026 ~ RADNOR, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that it has completed enrollmen...
- Jonathan Moreland
SBH SALLY BEAUTY HOLDINGS INC.
PRGO PERRIGO CO. PLC
NVCR NOVOCURE LTD.
KURA KURA ONCOLOGY INC.
GLP GLOBAL PARTNERS LP
FRPT FRESHPET INC
FLDM FLUIDIGM
FCN FTI CONSULTING INC.
CPRX CATALYST PHARMACEUTICALS
CE CELANESE CORPORATION
CDNA CAREDX INC
ASA ASA
AROW ARROW FINANCIAL CORP.
MDU MDU RESOURCES GROUP INC
ADC AGREE REALTY CORPORATION
CECE CECO ENVIRONMENTAL CORP.
ESP ESPEY MANUFACTURING & ELECTRONICS CORP.
BHB BAR HARBOR BANKSHARES
MFIN MEDALLION FINANCIAL CORP.
BSM BLACK STONE MINERALS LP
PLSE PULSE BIOSCIENCES
MLP MAUI LAND & PINEAPPLE CO. INC.
CELC CELCUITY
BRT BRT APARTMENTS
CCEL CRYO-CELL INTERNATIONAL
AEYE AUDIOEYE INC
DLHC DALEIGH HOLDINGS CORP
OPCH OPTION CARE HEALTH INC
SMMT SUMMIT THERAPEUTICS INC
CTO CONSOLIDATED-TOMOKA LAND CO
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
NAUT NAUTILUS BIOTECHNOLOGY INC
ENOV ENOVIS CORPORATION
PFHC PROFRAC HLDG CORP
MLYS MINERALYS THERAPEUTICS INC
PROP PRAIRIE OPERATING CO.
DMA DESTRA MULTI ALTERNATIVE FUND
CAMP CAMP4 THERAPEUTICS CORPORATION
SFD SMITHFIELD FOODS INC.
AFCG AFC GAMMA
HYMC INC.
NIQ HYCROFT MINING HOLDING CORPORATION
NIQ GLOBAL INTELLIGENCE PLC
- Jonathan Moreland
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HT...
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need ~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~ ~Subgroups - including Black or African American adults, older adults, women, and participants with comorbid obesity – face heightened risk of poor cardiovascular outcomes and represent high unmet need~ ~Lorundrostat demonstrated signifi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.